Companies: 10,795·Total market cap: $144.5T
ADMA Biologics, Inc.

ADMA Biologics, Inc.

ADMANASDAQHealthcare● Active
$8.07
+$0.10(+1.26%)
Market Cap$1.9B
P/E Ratio
52W High$22.37
52W Low$7.21
SEC Filings

ADMA Biologics, Inc. (ADMA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001368514 · ADMA · NASDAQ · as of Jun 8, 2026

Filing snapshot

990
Total Filings
8-K
Latest Form
2026-06-02
Most Recent
2013
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001368514 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-25
Fiscal Year End
Feb 25, 2026
Accession No.
0001140361-26-006815
Primary Document
ef20059416_10-k.htm
Source: data.sec.gov · CIK 0001368514 · Accession 0001140361-26-006815

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
8-KCurrent Report
8-K
2026-06-02Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-02
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
8-KCurrent Report
8-K
2026-05-04
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-29
View
ARSARS
ARS
2026-04-15
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-15
View
DEF 14AProxy Statement
DEF 14A
2026-04-15
View
8-KCurrent Report
8-K
2026-03-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-02
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-02-26
View
10-KAnnual Report
10-K
2026-02-25
View
8-KCurrent Report
8-K
2026-02-25
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-12
View
Showing 1–15 of 634 filingsForm 4 / 144 hidden· 990 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001368514  |  Exchange: NASDAQ · Healthcare

ADMA Biologics, Inc. (NASDAQ: ADMA) has submitted 990 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001368514, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is ADMA Biologics, Inc.'s most comprehensive regulatory disclosure. The most recent ADMA Biologics, Inc. 10-K was filed on 2026-02-25 for fiscal year ending 2026. Historical ADMA 10-K annual reports are available from 2006 through 2026.

Investors researching ADMA Biologics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ADMA SEC Filings · 8 questions

ADMA Biologics, Inc. (ADMA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 990 filings and access original documents at no cost. ADMA Biologics, Inc.'s CIK is 0001368514.

ADMA SEC filingsADMA Biologics, Inc. SEC documentsfind ADMA 10-K